Literature DB >> 18021177

Dynamics of cell cycle phase perturbations by trabectedin (ET-743) in nucleotide excision repair (NER)-deficient and NER-proficient cells, unravelled by a novel mathematical simulation approach.

M Tavecchio1, C Natoli, P Ubezio, E Erba, M D'Incalci.   

Abstract

OBJECTIVES: Trabectedin (ET-743, Yondelis) is a natural marine product, with antitumour activity, currently in phase II/III clinical trials. Previous studies have shown that cells hypersensitive to ultraviolet (UV)-rays because of nucleotide excision repair (NER) deficiency, were resistant to trabectedin. The purpose of this study was to investigate whether this resistance was associated with different drug-induced cell cycle perturbations.
MATERIALS AND METHODS: An isogenic NER-proficient cellular system (CHO-AA8) and a NER-deficient one (CHO-UV-96), lacking functional ERCC-1, were studied. Flow cytometric assays showed progressive accumulation of cells in G2 + M phase in NER-proficient but not in NER-deficient cells. Applying a computer simulation method, we realized that the dynamics of the cell cycle perturbations in all phases were complex.
RESULTS: Cells exposed to trabectedin during G1 and G2 + M first experienced a G1 block, while those exposed in S phase were delayed in S and G2 + M phases but eventually divided. In the presence of functional NER, exit from the G1 block was faster; then, cells progressed slowly through S phase and were subsequently blocked in G2 + M phase. This G2 + M processing of trabectedin-induced damage in NER-proficient cells was unable to restore cell cycling, suggesting a difficulty in repairing the damage.
CONCLUSIONS: This might be due either to important damage left unrepaired by previous G1 repair, or that NER activity itself caused DNA damage, or both. We speculate that in UV-96 cells repair mechanisms other than NER are activated both in G1 and G2 + M phases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18021177      PMCID: PMC6760722          DOI: 10.1111/j.1365-2184.2007.00469.x

Source DB:  PubMed          Journal:  Cell Prolif        ISSN: 0960-7722            Impact factor:   6.831


  25 in total

1.  Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove.

Authors:  M Zewail-Foote; L H Hurley
Journal:  J Med Chem       Date:  1999-07-15       Impact factor: 7.446

2.  Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743.

Authors:  M Minuzzo; S Marchini; M Broggini; G Faircloth; M D'Incalci; R Mantovani
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

3.  Interpreting cell cycle effects of drugs: the case of melphalan.

Authors:  Monica Lupi; Paolo Cappella; Giada Matera; Claudia Natoli; Paolo Ubezio
Journal:  Cancer Chemother Pharmacol       Date:  2005-09-30       Impact factor: 3.333

4.  Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action.

Authors:  E Erba; D Bergamaschi; L Bassano; G Damia; S Ronzoni; G T Faircloth; M D'Incalci
Journal:  Eur J Cancer       Date:  2001-01       Impact factor: 9.162

5.  Microcomputer experience in analysis of flow cytometric DNA distributions.

Authors:  P Ubezio
Journal:  Comput Programs Biomed       Date:  1985

6.  The inefficiency of incisions of ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent.

Authors:  M Zewail-Foote; V S Li; H Kohn; D Bearss; M Guzman; L H Hurley
Journal:  Chem Biol       Date:  2001-11

7.  Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.

Authors:  R Garcia-Carbonero; J G Supko; J Manola; M V Seiden; D Harmon; D P Ryan; M T Quigley; P Merriam; J Canniff; G Goss; U Matulonis; R G Maki; T Lopez; T A Puchalski; M A Sancho; J Gomez; C Guzman; J Jimeno; G D Demetri
Journal:  J Clin Oncol       Date:  2004-04-15       Impact factor: 44.544

Review 8.  Regulation and mechanisms of mammalian double-strand break repair.

Authors:  Kristoffer Valerie; Lawrence F Povirk
Journal:  Oncogene       Date:  2003-09-01       Impact factor: 9.867

9.  Molecular and crystal structures of ecteinascidins: potent antitumor compounds from the Caribbean tunicate Ecteinascidia turbinata.

Authors:  Y Guan; R Sakai; K L Rinehart; A H Wang
Journal:  J Biomol Struct Dyn       Date:  1993-04

10.  In vitro schedule-dependency of myelotoxicity and cytotoxicity of Ecteinascidin 743 (ET-743).

Authors:  M Ghielmini; E Colli; E Erba; D Bergamaschi; S Pampallona; J Jimeno; G Faircloth; C Sessa
Journal:  Ann Oncol       Date:  1998-09       Impact factor: 32.976

View more
  6 in total

1.  Activity of trabectidin in desmoplastic small round cell tumor.

Authors:  Ana López-González; Blanca Cantos; Eva Tejerina; Mariano Provencio
Journal:  Med Oncol       Date:  2010-10-07       Impact factor: 3.064

2.  Pharmacodynamic modeling of combined chemotherapeutic effects predicts synergistic activity of gemcitabine and trabectedin in pancreatic cancer cells.

Authors:  Xin Miao; Gilbert Koch; Robert M Straubinger; William J Jusko
Journal:  Cancer Chemother Pharmacol       Date:  2015-11-25       Impact factor: 3.333

3.  Comparative analysis of multilineage properties of mesenchymal stromal cells derived from fetal sources shows an advantage of mesenchymal stromal cells isolated from cord blood in chondrogenic differentiation potential.

Authors:  Alice Pievani; Valeria Scagliotti; Francesca Maria Russo; Isabella Azario; Benedetta Rambaldi; Benedetto Sacchetti; Simona Marzorati; Eugenio Erba; Giovanni Giudici; Mara Riminucci; Andrea Biondi; Patrizia Vergani; Marta Serafini
Journal:  Cytotherapy       Date:  2014-05-01       Impact factor: 5.414

4.  Integrated experimental and simulation study of the response to sequential treatment with erlotinib and gemcitabine in pancreatic cancer.

Authors:  Paolo Ubezio; Francesca Falcetta; Laura Carrassa; Monica Lupi
Journal:  Oncotarget       Date:  2016-03-29

5.  Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms.

Authors:  Michela Romano; Matteo Giovanni Della Porta; Anna Gallì; Nicolò Panini; Simonetta Andrea Licandro; Ezia Bello; Ilaria Craparotta; Vittorio Rosti; Elisa Bonetti; Richard Tancredi; Marianna Rossi; Laura Mannarino; Sergio Marchini; Luca Porcu; Carlos M Galmarini; Alberto Zambelli; Marco Zecca; Franco Locatelli; Mario Cazzola; Andrea Biondi; Alessandro Rambaldi; Paola Allavena; Eugenio Erba; Maurizio D'Incalci
Journal:  Br J Cancer       Date:  2017-01-10       Impact factor: 7.640

6.  Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin.

Authors:  B Colmegna; S Uboldi; R Frapolli; S A Licandro; N Panini; C M Galmarini; Nadia Badri; V J Spanswick; J P Bingham; Konstantinos Kiakos; E Erba; J A Hartley; M D'Incalci
Journal:  Br J Cancer       Date:  2015-12-03       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.